Structured around the development of medical therapies for addressing serious respiratory diseases, Metera Pharmaceuticals is targeted at areas of high unmet medical need where either current therapies have had limited efficacy or even unfavorable safety profiles or where - by intervening earlier - the course of disease can be addressed and the patients assisted towards recovery. The firm's novel approach organizes around program for IPF, MPX-111 combining the benefits of a clinically proven mechanism of action with inhaled delivery of a novel small molecule therapeutic to improve effectiveness and safety for IPF patients. Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease affecting over 100,000 Americans and an estimated 5 million people worldwide. New anti-fibrotic treatments have improved the short-term prognosis for patients living with IPF, but there remains a significant need for more efficacious and better tolerated therapies.
